Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
The FDA throws out the company’s second attempt at an accelerated approval.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.